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Review Article
Thrombolytic therapy in Cerebral Venous Sinus Thrombosis
Ayeesha K. Kamal
Department of Medicine, The Aga Khan University Hospital, Karachi.

Abstract
The use of thrombolytic agents to rapidly lyse the
clot has emerged as a therapeutic modality, in concert with
interventional neuroradiologic approaches to deliver the
agent locally at the site of thrombosis.There are no randomized, double blind, placebo, controlled trials to support
thrombolysis as a first line therapy in patients with cerebral
venous sinus thrombosis compared to standard therapy
using anticoagulation with weight based dose adjusted
unfractionated Heparin. Numerous case reports and a single
non randomized trial have shown that it is comparatively
safe and may rescue patients who are deteriorating despite
anticoagulation with unfractionated Heparin. Consideration
must be given to the use of thrombolysis in this group. This
is an approach that must be restricted to centers with considerable experience in neurointerventional therapy.

Introduction
Cerebral Venous Thrombosis (CVT) is a rare disorder with protean manifestations. It was associated with a
mortality rate of 20% to 50% in older studies.1 However,
with the advent of MR venography, its wide range of manifestations, from relatively benign isolated pseudotumour
like syndrome to coma with malignant uncontrollable ICP
have begun to be recognized. It is now believed that the
mortality rate for CVT ranges from 11% to 30%.2 Thus the
prognosis is not uniformly poor.
The widespread accepted treatment for CVT is systemic anticoagulation with Heparin or Heparinoid
(LMWH).Anticoagulation is believed to be beneficial as it
possibly prevents further venous clot propagation. It is not
known, given the variability and unpredictable course of the
disease, whether this mode of treatment will prevent progression in all patients.
Thrombolytic administration represents an alternate
mode of therapy which may be used for patients with progression despite adequate anticoagulation, those with massive parenchymal haemorrhages to minimize the dose of
systemic anticoagulation, those with poor prognostic factors
on presentation, and finally those where the course is felt to
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be unpredictable with potentially dangerous deterioration.
Thrombolytics or fibrinolytics are agents which lyse
the formed clot. The platelet - fibrin composition of a specific thrombus depends on the local development of fibrin,
platelet activation, and regional blood flow. At arterial flow
rates, thrombi are predominantly platelet rich, and at venous
flow rates, more relevant to the pathology of CVT, coagulation seems to predominate. Thrombin (Factor II a) cleaves
fibrinogen to form fibrin which is the scaffolding for the
clot. Thrombus growth is limited by the endogenous fibrinolytic system. This system is composed of plasminogen,
Plasminogen Activators (PA) and their inhibitors. Plasmin
mediates the degradation of fibrin. All fibrinolytic agents
are essentially obligate plasminogen activators that have
variable electivity for clot bound fibrin. The two most common agents reportedly used in the setting of CVT are urokinase and recombinant tissue plasminogen activator (rTPA).
The first report of systemic thrombolytic administration for CVT is from 1971.3 This idea is not novel. The
development of neuroendovascular techniques has enabled
the possibility of direct lytic administration into the affected sinus with mechanical or rheolytic aspiration of the clot.
The clinical rationale for this approach is that the clot is
removed and the occluded sinus is opened rapidly during
the procedure. This rapid decanalization may potentially
improve the clinical outcome and decrease the morbidity
and secondary complications associated with CVT.
There are no randomized, double blind, prospective,
placebo controlled trials evaluating this approach to standard systemic anticoagulation. Canhao et al have reviewed
the literature until 2001, reporting 72 publications, involving 169 patients.4 One third of these patients had some
haemorrhage on their pretreatment CT or MRI scans,
whereas 32% of these patients were in coma. These case
series are non uniform and the treatment has been utilized in
both deteriorating patients plus those who had a good neurologic status but a large clot burden on angiogram.
Urokinase was the thrombolytic most frequently administered (76%). In the majority of cases the thrombolytic was
locally infused in the occluded sinus (88%). At discharge,
11 cases (7%; 95% CI 3-12%) were dependent and 9 cases
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Table 1. Thrombolytic Therapy for CVT.
Study
Wasay, et al 20015

Therapy

Venous Flow Restoration
after therapy

Subjects

Direct Urokinase vs.
Systemic Heparin

N=40

Urokinase group had better discharge neurologic function.

Urokinase ( n=20)

No deaths were attributed to either
Urokinase or Heparin.

Heparin (n=20)
Retrospective Comparison
Frey, et al 19997

Kim & Suh 19978

Direct TPA and I.V.
heparin

Direct TPA

Horowitz, et al 19959 Direct Urokinase

Spearman, et al

Direct Urokinase

Outcomes and Complication

N=12

Full in 6/12 partial in 3/12

Case Series

Failed in 3/12

Pretreatment ICH 3/12

S/SX improved in full and
partial flow

1/3 tx stopped drop in fbrinogen

N=9

Flow restored full 9/9

No haemorrhage or reocclusion

Case series
N=12

Flow restored full in 7/12

No haemorrhage or reocclusion

Case Series

Partial in 4/12

Pretreatment ICH 4/12
N=2

Failed in 1/12
Flow restored full in 2/2

No haemorrhage or reocclusion

Flow restored

No haemorrhage or reocclusion

Flow restored in all

Full recovery in all

199710

Case report

Gartzen, et all 199711 Direct Urokinase followed by I.V. heparin

N=1

Di rocco, et al 198112 Urokinase and heparin

N=5

2/3 failed flow restoration had worsening ICH

Case report
Case series

in 5% they were associate with clinical deterioration.
Extracranial haemorrhages occurred in 21%, but only 2%
required blood transfusion. The mortality rate of 9% is comparable with that of the European trial with LMWH (9%)
and compares favorably with the 7% in the heparin group of
the trial.
A single retrospective non randomized trial compared the outcomes of CVT treated by local urokinase
administration vs. dose adjusted heparin in 40 patients .The
patients were well matched for baseline factors , pretreatment neurologic function was slightly worse in the throm-

bolysis group. There were no deaths in either group. At discharge, 16 / 20 patients who received urokinase were neurologically normal vs. 9 / 20 in those treated with heparin. The
long term follow up is not reported. This group concluded
that the treatment was at least safe and possibly effective.5
The following table (Table 1) summarizes some of the case
series that used thrombolysis for CVST, most show flow
restoration and atleast no increase in mortality with the use
of these agents.
Another adjunctive approach that should be discussed in this context is the use of mechanical disruption,

Table 2. Mechanical thrombus disruption after incomplete or failed thrombolysis.
Study
Baker et al 200113

Chow et al 200014

Phillips et al 199515

Urokinase

Venous Flow Restoration
after therapy
Immediate improvement on
imaging studies N=5/5

Treatment N=4/5

Single intervention N=2/5

Mechanical disruption alone

Two interventions N= 2/5

N=1/5

Multiple (5) interventions
N=1/5

Therapy
Combined pharmalogical
(Urokinase/ heparin) and one
or mechanical (rheolytic and
ballon catheters) clot disrupton

Subjects
N=5

Mechanical (angiolytic- rhe- N=2
olytic) thrombectomy with
Pretreatment ICH
intra-artrial thrombolysis and
N=2/2
failed heparin

Flow restored full in 2/2

Peri-thrombus Urokinase
N=6 groups
infusion with mechanical wire Urokinase N=4
microsnare maceration of
Urokinase + mechanical
thrombus
Maceration N=2

Flow restored 6/6
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Outcome and complication
Complete recovery N=2/5
Residual neurologic deficit
N=2/5
Significant neurologic deficit
N= 1/5
No reported haemorrhage or
occlusion
Good neurological outcome
No reported haemorrhage or
occlusion
Good neurological outcome
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clot maceration and rheolytic suction to aspirate venous
clot. The application of the AngioJet catheter to the treatment of dural sinus thrombosis has many potential benefits.
First, the AngioJet catheter is one of the few available
options when high doses of thrombolytic agents are contraindicated. Even locally delivered thrombolytic agents can
require a substantial amount of time to completely lyse a
massive clot; previous studies have documented thrombolytic infusions of 88 to 244 hours. Because the walls of
the sinuses are thick dura mater, with a low risk of rupture,
catheterization of all sinuses with the AngioJet catheter is
relatively safe. This is not the case, however, for cerebral
veins or the vein of Galen. The walls of these structures are
thin and fragile and associated with an increased risk of rupture and cerebral haemorrhage. Therefore, thrombi in these
locations should not be treated with the AngioJet and are
ideally lysed with the direct infusion of thrombolytic agents
such as urokinase. Table 2 Summarizes the data emerging
from some of the studies employing a mechanical approach
to lysis.

and in experienced centers, effective for those with a poor
prognosis. A large international multicenter trial comparing
the two treatments is warranted.
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